KEY POLICIES AND MEASURES OF HIV PREVENTION AND CONTROL AT GLOBAL LEVEL
Abstract
During the last 40 years, the development of medical HIV and AIDS related knowledge has been followed by a coordinated international HIV response, in terms of developing policies and measures for the HIV/AIDS prevention and control based on evidence from public health and clinical studies. The HIV response can be divided into three periods: the period of HIV response establishment (1981-1996); the period of multisectoral response (1996-2007) and the period of strengthening biomedical measures for HIV prevention (2007 and beyond). International policies and recommended HIV prevention measures have undergone a series of transformations, from the establishment of the first organized and coordinated national programs, to the design and implementation of innovative biomedical prevention measures, such as voluntary medical circumcision, pre-exposure prophylaxis and the implementation of the "test and treat" measure - the introduction of antiretroviral therapy immediately after diagnosing HIV infection to achieve undetectable viral load. New findings on successful use of antiretroviral therapy as prevention led to the formulation of goals for 2020: 90% of all people living with HIV to know their HIV status, 90% of them to receive antiretroviral therapy, and 90% of them to have viral suppression; to have less than 500,000 of both newly HIV infected persons, and AIDS related deaths. Despite of the HIV response major improvements, such as development and implementation of multisectoral national HIV/AIDS policies on prevention and control, the 2020 goals have not been meet. For achieving the main goal - ending AIDS as public health treat by 2030, implementation of all recommended biomedical, behavioral and structural interventions should be intensifying.
References
1. Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C. Hiv-2 molecular epidemiology. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2016;46:233-40.
2. Simić D. Epidemiološke odlike infekcije virusom humane imunodeficijencije i sindroma stečene imunodeicijencije. U: Jevtović Đ, urednik. HIV infekcija: Priručnik za lekare. Beograd: Institut za javno zdravlje Srbije "Dr Milan Jovanović Batut"; 2007. p. 6-20.
3. Jevtović Đ. HIV infekcija: Početni pristup i dalji tretman pacijenata sa infekcijom virusom humane imunodeficijencije. U: Jevtović Đ, urednik. HIV infekcija: priručnik za lekare. Beograd: Institut za javno zdravlje Srbije "Dr Milan Jovanović Batut"; 2007. p. 31-46.
4. Centers for Disease Prevention and Control. Ways HIV can be transmitted Atlanta, USA: CDC; 2022 [ažurirano 4. mart 2022, pristupljeno 11. avgust 2022]. Dostupno na: https://www.cdc.gov/hiv/basics/hiv-transmission/ways-people-get-hiv.html.
5. Joint United Nations Programme on HIV/AIDS. Fact sheet 2022: Latest global and regional statistics on the status of the AIDS epidemic Geneva: UNAIDS; 2022 [ažurirano 27. jul2022, pristupljeno 20. septembar 2022]. Dostupno na: https://www.unaids.org/en/resources/documents/2022/UNAIDS_FactSheet.
6. Centers for Disease Prevention and Control. Pneumocystis pneumonia - Los Angeles. Morbidity and mortality weekly report. 1981;30(21):250-2.
7. Centers for Disease Prevention and Control. Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Man - New York City and California. Morbidity and mortality weekly report. 1981;30(25):305-8.
8. Centers for Disease Prevention and Control. A Cluster of Kaposi's Sarcoma and Pneumocystit carinii Pneumonia among Homosexual Male Resident of Los Angeles and Orange Counties, California. MMWR Morbidity and mortality weekly report. 1982;31(23):305-7.
9. New York Times. New Homosexual Disorder Worries Health Officials. New York Times. 1982, 11. maj 1982.
10. Centers for Disease Prevention and Control. Update on Aquired Immune Deficiency Syndrome (AIDS) - United States. MMWR Morbidity and mortality weekly report. 1982;31(37):507-14.
11. Centers for Disease Prevention and Control. Update: Acyuired Immunodeiciency Syndrome (AIDS) - United States. MMWR Morbidity and mortality weekly report. 1983;32(35).
12. Centers for Disease Prevention and Control. Aquired Immunodeficiency Syndrome (AIDS) Update - United States. MMWR Morbidity and mortality weekly report. 1983;32(24):309-11.
13. World Health Organization. Acquired immunodeficiency syndrome--an assessment of the present situation in the world: memorandum from a WHO meeting. Bull World Health Organ. 1984;62(3):419-32.
14. Centers for Disease Prevention and Control. Recommendations for Assisting in the Prevention of Perinatal Transmission of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus and Acyuired Immunodeficiency Syndrome. MMWR Morbidity and mortality weekly report. 1985;34(48):721-31.
15. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):868-71.
16. Montagnier L, Dauguet C, Axler C, Chamaret S, Gruest J, Nugeyre MT, et al. A new type of retrovirus isolated from patients presenting with lymphadenopathy and acquired immune deficiency syndrome: Structural and antigenic relatedness with equine infectious anaemia virus. Annales de l'Institut Pasteur / Virologie. 1984;135(1):119-34.
17. Broder S, Gallo RC. A pathogenic retrovirus (HTLV-III) linked to AIDS. The New England journal of medicine. 1984;311(20):1292-7.
18. Marx J. Strong new candidate for AIDS agent. Science. 1984;224(4648):475-7.
19. Case K. Nomenclature: human immunodeficiency virus. Ann Intern Med. 1986;105(1):133.
20. Clavel F, Guétard D, Brun-Vézinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986;233(4761):343-6.
21. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011;1(1):a006841-a.
22. Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, Ward MJ, et al. HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science. 2014;346(6205):56-61.
23. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010;85(1):1-18.
24. Dujić A. Od prvog slučaja HIV/AIDS-a u Srbiji do formiranja Nacionalne komisije. U: Šulović V, Cucić V, Ilic D, urednici. Naučni skup: Dvadeset godina HIV/AIDS-a u Srbiji; Beograd: Srpska akademija nauke i umetnosti - Međuodeljenski odbor za SIDU, Asocijacija za borbu protiv SIDE - JAZAS; 2006. p. 13-24.
25. Kim YS. World Health Organization and Early Global Response to HIV/AIDS: Emergence and Development of International Norms. Journal of International and Area Studies. 2015;22(1):19-40.
26. Knight L. UNAIDS: The First 10 Years 1996-2007. Geneva, Swityerland: UNAIDS; 2008.
27. Mann JM, Kay K. Confronting the pandemic: the World Health Organization's Global Programme on AIDS, 1986-1989. AIDS (London, England). 1991;5 Suppl 2:S221-9.
28. Mann JM. The World Health Organization's global strategy for the prevention and control of AIDS. West J Med. 1987;147(6):732-4.
29. HIV.gov. A Timeline of HIV and AIDS: HIV.gov; n.d. [updated n.d.; cited 2020 17 jun]. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline.
30. Centers for Disease Prevention and Control. Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS): Report of Inter-Agency Recommendations. MMWR Morbidity and mortality weekly report. 1983;32(8):101-3.
31. Centers for Disease Prevention and Control. Provisional Public Health Services Inter-Agency Recommendations for Sreening Donated Blood and Plasma for Antibody to the Virus Causing Acquired Immunodeficiency Syndrome. MMWR Morbidity and mortality weekly report. 1985;34(1):1-5.
32. Witteveen E, Schippers G. Needle and syringe exchange programs in Amsterdam. Substance use & misuse. 2006;41(6-7):835-6.
33. Gay Men’s Health Crisis (GMHC). Syringe exchange programs around the world: The global context. New York: Gay Men’s Health Crisis; 2009.
34. Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Annali dell'Istituto superiore di sanita. 2011;47(1):44-8.
35. Delaney M. History of HAART – the true story of how effective multi-drug therapy was developed for treatment of HIV disease. Retrovirology. 2006;3(Suppl 1):S6-S.
36. United Nations. The Millenium Development Goals Report 2015. New York: 2015.
37. Joint United Nations Programme on HIV/AIDS/World Health Organization. Guidelines for Second Generation HIV Surveillance. Geneva: UNADIS/WHO Working Group on Global HIV/AIDS and STI Surveillance 2000.
38. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations: WHO; 2016.
39. Joint United Nations Programme on HIV/AIDS. The 'Three Ones' key principles. Geneva: UNAIDS; n.d. p. 2.
40. United Nations. Declaration of Commitment on HIV/AIDS; Adopted by General Assembly resolution S-26/2 of 27 June 2001: United Nationas Human Rights Office o the High Commissioner; 2001 [pristupljeno 10. jul 2022]. Dostupno na: https://www.ohchr.org/EN/ProfessionalInterest/Pages/CommitmentOnHIVAIDS.aspx.
41. World Health Organization. WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention [Internet]. World Healht Organization site: World Health Organization; 2007 [ažurirano 28. mart 2007; pristupljeno 1. oktobar 2022]. Dostupno na: https://www.who.int/hiv/mediacentre/news68/en/.
42. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial. PLOS Medicine. 2005;2(11):e298.
43. Baker J, OʼHara KM. Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications. JAAPA : official journal of the American Academy of Physician Assistants. 2014;27(12):10-7.
44. Weber J, Tatoud R, Fidler S. Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS (London, England). 2010;24 Suppl 4:S27-39.
45. Mayer K, Gazzard B, Zuniga JM, Amico KR, Anderson J, Azad Y, et al. Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. Journal of the International Association of Providers of AIDS Care. 2013;12(3):208-16.
46. Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Current opinion in infectious diseases. 2012;25(1):51-7.
47. Jourdain H, de Gage SB, Desplas D, Dray-Spira R. Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study. The Lancet Public Health. 2022;7(6):e529-e36.
48. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. New England Journal of Medicine. 2016;375(9):830-9.
49. Joint United Nations Programme on HIV/AIDS. Undetectable = Untransmittable: Public Health and HIV Viral Supression Geneva: UNAIDS; 2018 [updated 20. juli 2018. Available from: https://www.unaids.org/en/resources/presscentre/featurestories/2018/july/undetectable-untransmittable.
50. World Health Organization. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for public health approach. Gneva: World Health Organization; 2013.
51. World Health Organization. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for public health approach - Second Edition. Geneva: World Health Organization; 2016.
52. Joint United Nations Programme on HIV/AIDS. 90-90-90: An ambitious treatment target to help end AIDS epidemic. Geneva: Joint United Nations Program on HIV/AIDS (UNAIDS); 2014.
53. United Nations. Susteinable Development Goals: 3 - Ensure healthy lives and promote well-being for all at all ages: United Nations; 2015 [pristupljeno 29. septembar 2022]. Dostupno na: https://sdgs.un.org/goals/goal3.
54. Joint United Nations Programme on HIV/AIDS. 2016-2021 Strategy: On the Fast-Track to end AIDS. Geneva: UNAIDS; 2016.